Somatic mutations of cell-free circulating DNA detected by next-generation sequencing reflect the genetic changes in both germinal center B-cell-like and activated B-cell-like diffuse large B-cell lymphomas at the time of diagnosis.

Dynamic monitoring of circulating tumor DNA in non-Hodgkin lymphoma. Blood (2016) 0.94

Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma. Blood (2016) 0.80

Detection and prognostic value of recurrent exportin 1 mutations in tumor and cell-free circulating DNA of patients with classical Hodgkin lymphoma. Haematologica (2016) 0.79

Aberrant methylation of cell-free circulating DNA in plasma predicts poor outcome in diffuse large B cell lymphoma. Clin Epigenetics (2016) 0.77

Liquid biopsies for liquid tumors: emerging potential of circulating free nucleic acid evaluation for the management of hematologic malignancies. Cancer Biol Med (2016) 0.76

XPO1 in B cell hematological malignancies: from recurrent somatic mutations to targeted therapy. J Hematol Oncol (2017) 0.75

Evolution of lymphoma staging and response evaluation: current limitations and future directions. Nat Rev Clin Oncol (2017) 0.75

Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol (2014) 4.76

IgH gene rearrangements as plasma biomarkers in Non- Hodgkin's lymphoma patients. Oncotarget (2011) 2.34

Diffuse large B-cell lymphoma-treatment approaches in the molecular era. Nat Rev Clin Oncol (2013) 1.73

Minimal residual disease quantification using consensus primers and high-throughput IGH sequencing predicts post-transplant relapse in chronic lymphocytic leukemia. Leukemia (2013) 1.45

Detection of circulating tumour DNA in patients with aggressive B-cell non-Hodgkin lymphoma. Br J Haematol (2013) 1.12

Immunoglobulin and T cell receptor gene high-throughput sequencing quantifies minimal residual disease in acute lymphoblastic leukemia and predicts post-transplantation relapse and survival. Biol Blood Marrow Transplant (2014) 1.11

Cell-free circulating DNA in Hodgkin's and non-Hodgkin's lymphomas. Ann Oncol (2009) 1.03

Interim positron emission tomography scan associated with international prognostic index and germinal center B cell-like signature as prognostic index in diffuse large B-cell lymphoma. Leuk Lymphoma (2011) 0.96

Plasma cell-free DNA in paediatric lymphomas. J Cancer (2013) 0.92

Tumor-specific but not nonspecific cell-free circulating DNA can be used to monitor disease response in lymphoma. Am J Hematol (2011) 0.92

Targetable activating mutations are very frequent in GCB and ABC diffuse large B-cell lymphoma. Genes Chromosomes Cancer (2013) 0.91

Newly identified mechanisms in B-cell non-Hodgkin lymphomas uncovered by next-generation sequencing. Semin Hematol (2013) 0.89

Single molecule quantitation and sequencing of rare translocations using microfluidic nested digital PCR. Nucleic Acids Res (2013) 0.88

TP53 mutations in circulating free DNA from Egyptian patients with non-Hodgkin's lymphoma. Cancer Lett (2008) 0.87